Subscribe
Golden Shrimp / Shutterstock.com
5 September 2024NewsAmericasMarisa Woutersen

AstraZeneca unit draws line under Samsung dispute

AstraZeneca unit and Samsung Bioepis resolve their patent dispute over a biosimilar | Settlement follows FDA approval for the generic drug in July 2024 | Agreement dismisses ongoing litigation and appeals, including a federal lawsuit and related patent reviews.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Samsung Biologics faces suit from Amgen over bone biosimilars
15 August 2024   Amgen alleges infringement by proposed biosimilar versions of Prolia and XGEVA | Complaint accuses Samsung of failing to fully disclose biosimilar application and seeks injunction on bone-treatment products.
Big Pharma
Regeneron prevails in eye treatment dispute and immediately launches new suit
2 January 2024   District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents.
Big Pharma
AstraZeneca prevails in GSK royalties row at UK High Court
6 April 2023   Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.


Editor's picks

Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025

Editor's picks

Americas
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant
3 April 2025
Americas
‘We need the top 50 law firms to stand up’: Will Perkins Coie ignite Trump resistance?
13 March 2025
Americas
Trouble at the USPTO—Part I: Why government cutbacks are making everyone nervous
6 March 2025
Americas
‘Lift as you climb’: Abbott, BMS, Hitachi, LEGO Group counsels explore ‘empowerment’
6 March 2025
Careers
Jones Day adds experienced patent litigators from Weil
4 March 2025
Americas
LSPN finalists revealed for first-ever US awards
3 March 2025

More on this story

Americas
Samsung Biologics faces suit from Amgen over bone biosimilars
15 August 2024   Amgen alleges infringement by proposed biosimilar versions of Prolia and XGEVA | Complaint accuses Samsung of failing to fully disclose biosimilar application and seeks injunction on bone-treatment products.
Big Pharma
Regeneron prevails in eye treatment dispute and immediately launches new suit
2 January 2024   District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents.
Big Pharma
AstraZeneca prevails in GSK royalties row at UK High Court
6 April 2023   Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.

More on this story

Americas
Samsung Biologics faces suit from Amgen over bone biosimilars
15 August 2024   Amgen alleges infringement by proposed biosimilar versions of Prolia and XGEVA | Complaint accuses Samsung of failing to fully disclose biosimilar application and seeks injunction on bone-treatment products.
Big Pharma
Regeneron prevails in eye treatment dispute and immediately launches new suit
2 January 2024   District judge ruled in favour of Regeneron confirming patent infringement by Mylan | Court recognised Mylan's success in challenging the validity of certain patents | Ruling happened while Regeneron filed a separate case against another competitor alleging the infringement of 51 patents.
Big Pharma
AstraZeneca prevails in GSK royalties row at UK High Court
6 April 2023   Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.

More features

BMS notches legal win and FDA nod
AstraZeneca fends off diabetes generic, for now
Patent pledges in global crises: Why Moderna prevailed over Pfizer/BioNTech
EPO: Biotech innovation strong, while pharma trails behind
LSPN chair: Uncertainty lies ahead for life sciences
UPC issues sweeping injunction against Meril in heart valve case
PierFerd taps pharma and biotech patent expert from Weiss & Arons
Patent attorneys by day, coders by night: Sterne Kessler launches ‘homemade’ AI assistant